粪便钙卫蛋白用于预测克罗恩病患者的复发和活动：一项荟萃分析
Fecal Calprotectin for predicting Relapse and Activity in Patients with Crohn's Disease: A Meta-analysis.
作者信息
Zhuge Ying, Huang Qiu-Ping, Li Qing, Wang Jun-Shan
机构信息
Department of Cardiology, Affiliated Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai, China.
Department of Internal Medicine, Affiliated Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai, China.
出版信息
Euroasian J Hepatogastroenterol. 2016 Jul-Dec;6(2):116-124. doi: 10.5005/jp-journals-10018-1182. Epub 2016 Dec 1.
AIMS
We aimed to perform a meta-analysis of the predictive capacity of fecal calprotectin (FC) in activity and relapse of Crohn's disease (CD).
MATERIALS AND METHODS
MEDLINE, EMBASE, and the Cochrane Library databases were searched systematically. Pooled sensitivity, specificity, and other diagnostic indices were evaluated.
RESULTS
A total of 1,252 CD patients from 18 different studies were analyzed. The pooled sensitivity and specificity of FC at a cutoff value of 50 μg/g to predict activity of CD were 0.91 [95% confidence interval (CI): 0.87-0.95] and 0.47 (95% CI: 0.35-0.59) respectively. The pooled sensitivity and specificity of FC at a cutoff value of larger than 150 μg/g to monitor relapse of CD was 0.75 (95% CI: 0.67-0.82) and 0.71 (95% CI: 0.66-0.76) respectively. The area under the summary receiver operating characteristic (SROC) curve of FC for detecting CD activity was 0.78 (50 μg/g), 0.88 (100 μg/g), 0.85 (>150 μg/g), and the diagnostic odds ratio (DOR) was 10.21 (50 μg/g), 10.20 (100 μg/g), 11.68 (>150 μg/g) respectively.
CONCLUSION
As a simple and noninvasive marker, FC is useful to predict the activity and relapse in CD patients, and the capacity of FC to predict CD activity was superior to its application in monitoring relapse of CD.
HOW TO CITE THIS ARTICLE
Zhuge Y, Huang Q-P, Li Q, Wang J-S. Fecal Calprotectin for predicting Relapse and Activity in Patients with Crohn's Disease: A Meta-analysis. Euroasian J Hepato-Gastroenterol 2016;6(2):116-124.
目的
我们旨在对粪便钙卫蛋白（FC）在克罗恩病（CD）活动期和复发方面的预测能力进行荟萃分析。
材料与方法
系统检索MEDLINE、EMBASE和Cochrane图书馆数据库。评估合并敏感度、特异度及其他诊断指标。
结果
共分析了来自18项不同研究的1252例CD患者。FC以50μg/g为临界值预测CD活动期的合并敏感度和特异度分别为0.91[95%置信区间（CI）：0.87 - 0.95]和0.47（95%CI：0.35 - 0.59）。FC以大于150μg/g为临界值监测CD复发的合并敏感度和特异度分别为0.75（95%CI：0.67 - 0.82）和0.71（95%CI：0.66 - 0.76）。FC检测CD活动期的汇总受试者工作特征（SROC）曲线下面积分别为0.78（50μg/g）、0.88（100μg/g）、0.85（>150μg/g），诊断比值比（DOR）分别为10.21（50μg/g）、10.20（100μg/g）、11.68（>150μg/g）。
结论
作为一种简单且无创的标志物，FC对预测CD患者的活动期和复发有用，且FC预测CD活动期的能力优于其在监测CD复发方面的应用。
如何引用本文
Zhuge Y, Huang Q-P, Li Q, Wang J-S. Fecal Calprotectin for predicting Relapse and Activity in Patients with Crohn's Disease: A Meta-analysis. Euroasian J Hepato-Gastroenterol 2016;6(2):116 - 124.
Zotero 插件